Program
Pemetrexed
Also written as “pemetrexed”, “ALIMTA” and “Pemetrexed/Cisplatin”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 940 open or running | phase 4since Sep 22, 2006 | Apr 29, 2002 | none ahead |
| Hoffmann-La Roche | 72 open or running | phase 3since Aug 18, 2009 | Aug 18, 2009 | Jun 30, 2027phase 3 · NCT05112965 |
| Betta Pharmaceuticals | 10 open or running | phase 4since Mar 31, 2014 | Mar 31, 2014 | none ahead |
| Hikma Pharmaceuticals | 10 open or running | phase 4since Feb 26, 2018 | Feb 26, 2018 | none ahead |
| Johnson & Johnson | 11 open or running | phase 3since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| NovoCure | 10 open or running | phase 2since Mar 19, 2015 | Mar 19, 2015 | none ahead |
| polaris-group | 10 open or running | phase 3since Mar 5, 2016 | Mar 5, 2016 | none ahead |
| shanghai-miracogen-inc | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Takeda | 10 open or running | phase 2since Jun 22, 2006 | Jun 22, 2006 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, parexel, Daiichi Sankyo, Arcus Biosciences, Ono Pharmaceutical and prologue-research-international.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since May 10, 2006.
- Jul 8, 20102 phase 2 studies in Carcinoma, Non-Small-Cell LungEli Lilly · NCT01160744, NCT01165021
- Aug 19, 2010Phase 2 study in Non-Squamous Non-Small Cell Lung CancerHoffmann-La Roche · NCT01185847 · 90 enrolled · Belgium, France, Germany and more
- Nov 2, 20112 phase 2 studies in Carcinoma, Non-Small-Cell LungEli Lilly · NCT01473563, NCT01469000
- Dec 19, 2011Phase 2 study in Non-Squamous Non-Small Cell Lung CancerHoffmann-La Roche · NCT01496742 · 259 enrolled · United States, Argentina, France and more
- Mar 31, 2014Betta Pharmaceuticals's first study: phase 4 study in AdenocarcinomaNew to Betta PharmaceuticalsBetta Pharmaceuticals · NCT02103257 · 192 enrolled · China
- Mar 19, 2015NovoCure's first study: phase 2 study in Mesothelioma, MalignantNew to NovoCureNovoCure · NCT02397928 · 82 enrolled · Belgium, France, Germany and more
- Mar 5, 2016polaris-group's first study: phase 3 study in MesotheliomaNew to polaris-grouppolaris-group · NCT02709512 · 249 enrolled · United States, Australia, Italy and more
- Jun 5, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552 · 1,000 enrolled · United States, Argentina, Australia and more
- Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03337698 · 314 enrolled · United States, Australia, France and more
- Feb 26, 2018Hikma Pharmaceuticals's first study: phase 4 study in Carcinoma, Non-Small-Cell LungNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT03460678 · 9 enrolled · Jordan, Lebanon
- Aug 31, 2020Johnson & Johnson's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Johnson & JohnsonJohnson & Johnson · NCT04538664 · 308 enrolled · United States, Australia, Belgium and more
- Nov 2, 2021Phase 3 study in NeoplasmsHoffmann-La Roche · NCT05112965 · 49 enrolled · China
- Feb 22, 2023shanghai-miracogen-inc's first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to shanghai-miracogen-incshanghai-miracogen-inc · NCT05754853 · 290 planned · China
- Oct 1, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT06624059 · 11 enrolled · Australia, Brazil, Chile and more
Ahead
- Jun 30, 2027Primary completion: phase 3 study in NeoplasmsHoffmann-La Roche · NCT05112965
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552
TargetBeta
“Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 108 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06624059Carcinoma, Non-Small-Cell Lung · Australia, Brazil, Chile and more | 3 | Completed | Hoffmann-La Roche | Jul 31, 2026 | 11 |
| NCT05754853Advanced or Metastatic Urothelium Cancer · China | 3 | Recruiting | shanghai-miracogen-inc | Oct 2025 | 290 |
| NCT05112965Neoplasms · China | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 49 |
| NCT04538664Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | May 3, 2023 | 308 |
| NCT03460678Carcinoma, Non-Small-Cell Lung · Jordan, Lebanon | 4 | Terminated | Hikma Pharmaceuticals | Nov 14, 2018 | 9 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 1,000 |
| NCT02709512Mesothelioma · United States, Australia, Italy and more | 3 | Completed | polaris-group | Aug 15, 2022 | 249 |
| NCT02397928Mesothelioma, Malignant · Belgium, France, Germany and more | 2 | Completed | NovoCure | Apr 2018 | 82 |
| NCT02103257Adenocarcinoma · China | 4 | UNKNOWN | Betta Pharmaceuticals | Mar 2016 | 192 |
| NCT01496742Non-Squamous Non-Small Cell Lung Cancer · United States, Argentina, France and more | 2 | Completed | Hoffmann-La Roche | Nov 2015 | 259 |
| NCT01469000Carcinoma, Non-Small-Cell Lung · China, Japan, Korea, Republic of and more | 2 | Completed | Eli Lilly | Apr 2015 | 195 |
| NCT01473563Carcinoma, Non-Small-Cell Lung · Sweden, United Kingdom | 2 | Completed | Eli Lilly | Sep 2013 | 52 |
| NCT01185847Non-Squamous Non-Small Cell Lung Cancer · Belgium, France, Germany and more | 2 | Completed | Hoffmann-La Roche | Sep 2012 | 90 |
| NCT01165021Carcinoma, Non-Small-Cell Lung · Italy | 2 | Completed | Eli Lilly | Jul 2013 | 19 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Jan 2014 | 280 |
| NCT01087970Head and Neck Neoplasms · United States | 2 | Completed | Eli Lilly | Aug 2013 | 69 |
| NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more | 2 | Completed | Eli Lilly | Feb 2012 | 66 |
| NCT01020786Carcinoma, Non-Small-Cell Lung · Japan | 4 | Completed | Eli Lilly | Mar 2011 | 109 |
| NCT01017874Carcinoma, Non-Small-Cell Lung · Hong Kong, Korea, Republic of, Singapore and more | 3 | Completed | Eli Lilly | Apr 2013 | 236 |
| NCT01005680Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Eli Lilly | Nov 2012 | 256 |
| NCT01004250Carcinoma, Non-Small-Cell Lung · Denmark, Germany, Italy and more | 2 | Completed | Eli Lilly | Nov 2012 | 109 |
| NCT01000480Carcinoma, Non-Small-Cell Lung · France, Germany, Italy and more | 2 | Completed | Eli Lilly | Jan 2013 | 90 |
| NCT00961415Non-Squamous Non-Small Cell Lung Cancer · France, Germany, Greece and more | 3 | Completed | Hoffmann-La Roche | May 2011 | 376 |
| NCT00948675Carcinoma, Non-Small-Cell Lung · United States | 3 | Completed | Eli Lilly | Jan 31, 2013 | 361 |
| NCT00887549Carcinoma, Non-Small-Cell Lung · Ireland, United Kingdom | 2 | Completed | Eli Lilly | Jul 2010 | 70 |
| NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more | 2 | Completed | Eli Lilly | May 2011 | 113 |
| NCT00789373Carcinoma, Non-Small-Cell Lung · Australia, Belgium, Finland and more | 3 | Completed | Eli Lilly | Jun 2010 | 939 |
| NCT00762034Carcinoma, Non-Small-Cell Lung · United States | 3 | Completed | Eli Lilly | Apr 2012 | 939 |
| NCT00686959Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Oct 2014 | 598 |
| NCT00606021Carcinoma, Non-Small-Cell Lung · Egypt, Lebanon, Saudi Arabia | 2 | Completed | Eli Lilly | Dec 2010 | 106 |
| NCT00550173Carcinoma, Non-Small-Cell Lung · Brazil, China, Hong Kong and more | 2 | Completed | Eli Lilly | Jan 2012 | 247 |
| NCT00529100Carcinoma, Non-Small-Cell Lung · Canada | 2 | Completed | Eli Lilly | Aug 2010 | 49 |
| NCT00523419Osteosarcoma · France, Germany, Italy and more | 2 | Completed | Eli Lilly | Jun 2009 | 32 |
| NCT00520936Osteosarcoma · United States | 2 | Completed | Eli Lilly | Feb 2010 | 72 |
| NCT00520676Carcinoma, Non-Small-Cell Lung · Australia, Brazil, China and more | 3 | Completed | Eli Lilly | Jul 2010 | 260 |
| NCT00494026Small Cell Lung Carcinoma · Italy, Poland, Spain and more | 2 | Terminated | Eli Lilly | Oct 2008 | 4 |
| NCT00490373Pancreatic Neoplasms · Germany | 2 | Completed | Eli Lilly | 52 | |
| NCT00489983Carcinoma, Non-Small-Cell Lung · Germany, Italy, United Kingdom | 2 | Completed | Eli Lilly | 91 | |
| NCT00489359Ovarian Neoplasms · Argentina, Canada, Germany and more | 2 | Completed | Eli Lilly | Feb 2010 | 86 |
| NCT00475657Small Cell Lung Carcinoma · Spain | 2 | Terminated | Eli Lilly | Apr 2008 | 5 |
| NCT00461786Ovarian Neoplasms · United States | 2 | Completed | Eli Lilly | Oct 2007 | 51 |
| NCT00447421Small Cell Lung Carcinoma · Belgium, Netherlands | 2 | Terminated | Eli Lilly | May 2008 | 9 |
| NCT00447057Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. · Austria, Germany, Hungary and more | 2 | Completed | Eli Lilly | Jul 2010 | 204 |
| NCT00415194Head and Neck Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Mar 2010 | 795 |
| NCT00415168Stomach Neoplasms · Russian Federation | 2 | Completed | Eli Lilly | Jul 2009 | 53 |
| NCT00409006Carcinoma, Non-Small-Cell Lung · China, Korea, Republic of, Taiwan | 2 | Completed | Eli Lilly | Aug 2009 | 70 |
| NCT00391274Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Eli Lilly | Dec 2008 | 211 |
| NCT00386815Mesothelioma, Malignant · Japan | 2 | Completed | Eli Lilly | 20 | |
| NCT00383331Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Eli Lilly | Jan 2008 | 19 |
| NCT00380718Carcinoma, Non-Small-Cell Lung · Taiwan | 4 | Completed | Eli Lilly | Sep 2008 | 33 |
| NCT00377520Neoplasms · United States | 2 | Completed | Eli Lilly | Oct 2007 | 27 |
| NCT00374868Urologic Neoplasms · Spain | 2 | Completed | Eli Lilly | Apr 2008 | 59 |
| NCT00370292Carcinoma, Non-Small-Cell Lung · Italy | 2 | Completed | Eli Lilly | Sep 2008 | 19 |
| NCT00363415Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jun 2008 | 908 |
| NCT00356525Lung Neoplasms · United States, Brazil, India | 2 | Terminated | Eli Lilly | Jun 2008 | 41 |
| NCT00350792Carcinoma, Non-Small-Cell Lung · France | 2 | Completed | Eli Lilly | Nov 2008 | 62 |
| NCT00343720Carcinoma, Non-Small-Cell Lung · Belgium | 2 | Completed | Takeda | Oct 2007 | |
| NCT00330915Rectal Neoplasms · Sweden | 2 | Completed | Eli Lilly | Jun 2008 | 37 |
| NCT00325234Breast Neoplasms · Germany, Italy, South Africa and more | 2 | Completed | Eli Lilly | Apr 2010 | 135 |
How it is read
Names in the registry
- “Pemetrexed”, 74 entries
- “pemetrexed”, 51 entries
- “ALIMTA”, 7 entries
- “Pemetrexed/Cisplatin”, 2 entries
- “Pemetrexed/Carboplatin”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 73 studies
- Breast Neoplasms, 9 studies
- Neoplasms, 5 studies
- Ovarian Neoplasms, 4 studies
- Colorectal Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.